Gastroesophageal cancer is one of the most aggressive forms of the disease, and while effective treatments exist to control it, unfortunately only 1 in 10 patients diagnosed will beat the disease. The rate has been rising in the UK over the last 40 years and the rate of gastroesophageal cancer in Scotland is amongst the highest in the world. For these reasons, research to determine the causes and find better treatments are a medical priority.
The research team at the University of Aberdeen is supported by the fundraising efforts of GASTROCAN and focuses on gastroesophegal cancer. Their work involves clinical trials of the latest new targeted drugs for the disease as well as ‘bench to bedside’ laboratory research aiming to translate scientific breakthroughs into effective treatments. The clinical trials allow patients in the region to receive the latest and best treatments and the laboratory research helps to build on this best practice by finding the new more effective treatments of the future.
GASTROCAN is the only appeal raising money specifically for research into stomach and oesophageal cancer. All funds donated to the GASTROCAN appeal are used to support local research efforts into this devastating disease to benefit local patients and enable the University of Aberdeen to lead national and international research projects.
The main aims of GASTROCAN include:
- Undertaking internationally important cancer research locally in the north of Scotland
- Enabling local patients to benefit from the latest cutting edge treatments for gastric and oesophageal cancer
- Helping to recruit the best doctors and researchers to work in the north of Scotland
- Raising awareness of gastric and oesophageal cancer so that patients recognise the symptoms and seek medical help earlier
There are many ways to support GASTROCAN and to find out more please contact Lynne Black, Community Stewardship Officer on 01224 272087 or email firstname.lastname@example.org.
If you have a sponsored event in mind you can download a sponsor form here.